Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341390 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03341390 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants.
The verdict
NCT03341390, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of taking multiple doses of BMS-986177 when aspirin is taken once-daily. Eligible participants will receive twice-daily doses of BMS-986177 or placebo, with a once-daily dose of aspirin. The safety, tolerability and movement of BMS-986177 into, through and out of the body (pharmacokinetics/PK) will be assessed, as will the effect of BMS-986177 on the PK of aspirin.
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG BMS-986177
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2017-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341390
The ClinicalTrials.gov registry entry for NCT03341390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03341390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03341390 about?
NCT03341390 is a clinical study titled "An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants". The purpose of this study is to investigate the effect of taking multiple doses of BMS-986177 when aspirin is taken once-daily. Eligible participants will receive twice-daily doses of BMS-986177 or placebo, with a once-daily dose of aspirin. The safety, tolerability and movement of BMS-986177 into, ...
What is the current status of trial NCT03341390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-10-18. Estimated completion is 2017-11-16.
What interventions are being tested in trial NCT03341390?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), BMS-986177 (DRUG).
Who is sponsoring clinical trial NCT03341390?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.